Comparing GeneDx (NASDAQ:WGS) and Q Biomed (OTCMKTS:QBIO)

Q Biomed (OTCMKTS:QBIO) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Q Biomed and GeneDx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q Biomed	0	0	0	0	0.00
GeneDx	1	0	7	1	2.89

GeneDx has a consensus target price of $140.71, suggesting a potential upside of 112.56%. Given GeneDx’s stronger consensus rating and higher possible upside, analysts clearly believe GeneDx is more favorable than Q Biomed.

Volatility and Risk

Q Biomed has a beta of 2.53, indicating that its share price is 153% more volatile than the S&P 500. Comparatively, GeneDx has a beta of 2.17, indicating that its share price is 117% more volatile than the S&P 500.

Valuation & Earnings

This table compares Q Biomed and GeneDx”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q Biomed	N/A	N/A	N/A	($0.02)	N/A
GeneDx	$427.54 million	4.54	-$21.02 million	($0.75)	-88.27

Q Biomed has higher earnings, but lower revenue than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Q Biomed, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

61.7% of GeneDx shares are owned by institutional investors. 28.2% of Q Biomed shares are owned by insiders. Comparatively, 29.6% of GeneDx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Q Biomed and GeneDx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Q Biomed	N/A	N/A	N/A
GeneDx	-4.92%	14.73%	8.67%

Summary

GeneDx beats Q Biomed on 9 of the 12 factors compared between the two stocks.

About Q Biomed

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.